LTRN Stock Price, Lantern Pharma Inc Quote, Chart

Market Summary

USD6.21+0.72

Market Closed

13.11%

LTRN Stock Price

View Fullscreen

LTRN RSI Chart

LTRN Valuation

Market Cap

66.7M

Price/Earnings (Trailing)

-4.18

Price/Sales (Trailing)

87.15

Price/Free Cashflow

-4.64

LTRN Price/Sales (Trailing)

LTRN Profitability

Return on Equity

-39.02%

Return on Assets

-36.57%

Free Cashflow Yield

-21.54%

LTRN Fundamentals

LTRN Revenue

Revenue (TTM)

765.4K

LTRN Earnings

Earnings (TTM)

-16.0M

Earnings Growth (Yr)

-23.8%

Earnings Growth (Qtr)

-32.41%

Breaking Down LTRN Revenue

Last 7 days

12.9%

Last 30 days

-28.1%

Last 90 days

46.1%

Trailing 12 Months

24.2%

How does LTRN drawdown profile look like?

LTRN Financial Health

Current Ratio

16.18

LTRN Investor Care

Buy Backs (1Y)

1.07%

Diluted EPS (TTM)

-1.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	315.7K	378.5K	0	765.4K
2022	102.0K	136.1K	170.2K	204.4K
2021	0	0	0	67.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lantern Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	kreis leslie w.	sold	-8,921	4.87	-1,832	-
Feb 29, 2024	fletcher aaron g.l.	sold	-66,650	4.87	-13,686	-
Feb 29, 2024	kreis leslie w.	sold	-20,380	4.87	-4,185	-
Feb 29, 2024	kreis leslie w.	sold	-66,650	4.87	-13,686	-
Feb 29, 2024	fletcher aaron g.l.	sold	-20,380	4.87	-4,185	-
Feb 29, 2024	fletcher aaron g.l.	sold	-8,921	4.87	-1,832	-
Feb 28, 2024	fletcher aaron g.l.	sold	-76,533	4.85	-15,780	-
Feb 28, 2024	fletcher aaron g.l.	sold	-33,508	4.85	-6,909	-
Feb 28, 2024	fletcher aaron g.l.	sold	-250,299	4.85	-51,608	-
Feb 28, 2024	kreis leslie w.	sold	-250,299	4.85	-51,608	-

Which funds bought or sold LTRN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Sigma Planning Corp	added	126	185,455	236,280	0.01%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	sold off	-100	-252,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	-	119,703	233,040	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	25,000	25,000	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	452	880	-%
Apr 25, 2024	Meridian Wealth Management, LLC	sold off	-100	-84,145	-	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	105,635	105,635	-%
Apr 18, 2024	WOLFF WIESE MAGANA LLC	unchanged	-	2,712	5,280	-%
Apr 16, 2024	Indiana Trust & Investment Management CO	new	-	6,600	6,600	-%

Are Funds Buying or Selling LTRN?

Are funds buying LTRN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LTRN

No. of Funds

Unveiling Lantern Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 01, 2024	bios equity partners, lp	3.5%	371,950	SC 13D/A
Feb 14, 2024	prophase labs, inc.	8%	631,195	SC 13G/A
Dec 01, 2023	bios equity partners, lp	3.5%	371,950	SC 13D/A
Nov 21, 2022	prophase labs, inc.	8.4%	910,000	SC 13G
Jan 11, 2022	empery asset management, lp	0.00%	0	SC 13G/A
Feb 16, 2021	green park & golf ventures, llc	1.4%	147,502	SC 13G
Feb 16, 2021	asaithambi arunkumar	4.5%	470,460	SC 13G
Jan 25, 2021	empery asset management, lp	6.66%	7e+05	SC 13G

Recent SEC filings of Lantern Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 26, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 01, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Lantern Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Lantern Pharma Inc News

Latest updates

Lantern Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-100.0%	-	118	134	75.00	52.00	55.00	22.00	50.00	77.00	48.00
Operating Expenses	-6.0%	4,877	5,190	4,286	3,826	2,145	4,395	4,066	3,511	4,149	2,479
S&GA Expenses	-20.1%	1,304	1,632	1,733	1,575	1,443	1,406	1,406	1,349	1,184	1,314
R&D Expenses	0.4%	3,573	3,558	2,553	2,252	702	2,989	2,660	2,162	2,964	1,165
Net Income	11.8%	-4,185	-4,746	-3,867	-3,381	-2,264	-4,492	-4,121	-3,540	-4,053	-2,316
Net Income Margin	44.6%	-20.85*	-37.67*	-44.36*	-69.78*	-84.69*	-119.06*	-137.53*	-182.00*	-	-
Free Cashflow	5.6%	-3,390	-3,591	-3,766	-2,675	-4,044	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-8.6%	44.00	48.00	51.00	56.00	59.00	62.00	66.00	68.00	74.00	78.00	82.00	83.00	20.00	22.00	26.00	-
Current Assets	-8.6%	43.00	47.00	51.00	55.00	59.00	62.00	66.00	68.00	73.00	76.00	82.00	82.00	20.00	22.00	26.00	1.00
Cash Equivalents	-14.2%	22.00	26.00	28.00	32.00	37.00	39.00	43.00	47.00	52.00	55.00	61.00	81.00	19.00	21.00	24.00	1.00
Net PPE	2.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	16.1%	3.00	2.00	3.00	3.00	3.00	3.00	5.00	3.00	2.00	2.00	3.00	1.00	1.00	1.00	2.00	0.00
Current Liabilities	18.9%	3.00	2.00	3.00	3.00	3.00	3.00	5.00	3.00	2.00	2.00	3.00	1.00	1.00	1.00	2.00	0.00
Shareholder's Equity	-9.9%	41.00	45.00	48.00	53.00	56.00	59.00	61.00	65.00	72.00	76.00	80.00	82.00	20.00	22.00	23.00	1.00
Retained Earnings	-8.2%	-55.24	-51.06	-47.90	-43.15	-39.28	-35.90	-33.64	-29.14	-25.02	-21.48	-17.43	-15.11	-12.66	-9.76	-8.06	-6.75
Additional Paid-In Capital	-0.4%	96.00	97.00	96.00	96.00	96.00	95.00	95.00	95.00	97.00	97.00	97.00	97.00	32.00	31.00	31.00	8.00
Shares Outstanding	-1.4%	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	10.00	-	-	-	-
Float	-	-	-	53.00	-	-	-	51.00	-	-	-	122	-	-	-	35.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	6.3%	-3,385	-3,612	-3,591	-3,757	-2,668	-4,038	-2,732	-3,327	-2,039	-4,682	-1,725	-2,144	-1,568	-2,889	-490	-703	-	-	-
Share Based Compensation	-20.8%	151	191	392	334	330	301	290	267	246	224	246	246	-	-	-	-	-	-	-
Cashflow From Investing	10.6%	256	232	-457	-960	603	-74.36	-525	177	-233	-1,002	-	-	-4.99	-3.32	-	-	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-2,182	-872	-	-1*	64,289	-261*	-102	23,663	105	-	-	-
Buy Backs	-	-	-	-	-	-2,482	2,482	2,482	2,482	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LTRN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
General and administrative	$ 5,983,255	$ 5,829,799
Research and development	11,894,315	8,602,954
Total operating expenses	17,877,570	14,432,753
Loss from operations	(17,877,570)	(14,432,753)
Interest income	765,388	204,355
Other income (expense), net	1,150,648	(31,548)
NET LOSS	$ (15,961,534)	$ (14,259,946)
Net loss per share of common shares, basic	$ (1.47)	$ (1.31)
Net loss per share of common shares, diluted	$ (1.47)	$ (1.31)
Weighted-average number of common shares outstanding, basic	10,842,365	10,850,579
Weighted-average number of common shares outstanding, diluted	10,842,365	10,850,579

LTRN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 21,937,749	$ 37,201,786
Restricted cash		541,180
Marketable securities	19,364,923	17,994,299
Prepaid expenses & other current assets	2,038,653	2,985,472
Total current assets	43,341,325	58,722,737
Property and equipment, net	52,127	48,008
Operating lease right-of-use assets	228,295	47,687
Other assets	25,869	17,889
TOTAL ASSETS	43,647,616	58,836,321
CURRENT LIABILITIES
Accounts payable and accrued expenses	2,505,211	2,745,407
Operating lease liabilities, current	172,975	52,890
Total current liabilities	2,678,186	2,798,297
Operating lease liabilities, net of current portion	61,496
TOTAL LIABILITIES	2,739,682	2,798,297
COMMITMENTS AND CONTINGENCIES (NOTE 4)
STOCKHOLDERS’ EQUITY
Preferred Stock (1,000,000 authorized at December 31, 2023 and December 31, 2022; $.0001 par value) (Zero shares issued and outstanding at December 31, 2023 and December 31, 2022)
Common Stock (25,000,000 authorized at December 31, 2023 and December 31, 2022; $.0001 par value) (10,721,192 shares issued and outstanding at December 31, 2023; 10,857,040 shares issued and outstanding at December 31, 2022)	1,072	1,086
Additional paid-in capital	96,258,726	95,691,194
Accumulated other comprehensive loss	(107,460)	(371,386)
Accumulated deficit	(55,244,404)	(39,282,870)
Total stockholders’ equity	40,907,934	56,038,024
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 43,647,616	$ 58,836,321

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

CEO	Mr. Panna Sharma PH.D.
WEBSITE	lanternpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Lantern Pharma Inc Frequently Asked Questions

What is the ticker symbol for Lantern Pharma Inc? What does LTRN stand for in stocks?

LTRN is the stock ticker symbol of Lantern Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lantern Pharma Inc (LTRN)?

As of Fri May 03 2024, market cap of Lantern Pharma Inc is 66.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LTRN stock?

You can check LTRN's fair value in chart for subscribers.

What is the fair value of LTRN stock?

You can check LTRN's fair value in chart for subscribers. The fair value of Lantern Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lantern Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LTRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lantern Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LTRN is over valued or under valued. Whether Lantern Pharma Inc is cheap or expensive depends on the assumptions which impact Lantern Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LTRN.

What is Lantern Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, LTRN's PE ratio (Price to Earnings) is -4.18 and Price to Sales (PS) ratio is 87.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LTRN PE ratio will change depending on the future growth rate expectations of investors.